Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

IOVA Iovance Biotherapeutics, Inc. Common Stock
$2.50 3.28% +0.08
Notify me if price changes either direction
Interactive Brokers Logotype

Buy IOVA stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 996.4M
Enterprise value 720.3M
Trailing PE -1.9609374925494
Forward PE -3.9971168
PEG Ratio 0.18302083263795
Enterprise to EBITDA -1.917
Enterprise to revenue 2.876
Price to book MRQ 1.3391877
Price to sales TTM 3.8678322

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 250.4M
EBITDA -375784992
Diluted EPS TTM -1.19
Total Cash (MRQ) 300.8M
Current ratio (MRQ) 3.411
Operating Cash Flow (TTM) -323139008

IOVA trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent IOVA News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.